Skip to main content

Week in Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid

Deals and Financings • Sorrento Therapeutics, a San Diego-China immunotherapy company, rejected a $933 million take-private offer from an unnamed PE company; • Ocumension announced a $12 million agreement for China rights to Eyepoint Pharma's Dexycu® 9%, a treatment for inflammation following ocular surgery; • Biotheus, a Guangdong biotech, in-licensed greater China rights to an oncolytic virus drug candidate from Finland's TILT Biotherapeutics; • Ningbo NewBay Medical in-licensed greater China rights to a novel Pan-PIM inhibitor from Genentech for multiple myeloma and prostate cancer; Trials and Approvals • DelMar Pharma of San Diego announced its lead drug increased progression-free survival in a China Phase II trial for glioblastoma multiforme (GBM); • CSPC Pharma has begun a China bridging trial of Copiktra®, a Verastem drug, in patients with relapsed or refractory follicular lymphoma; • CStone Pharma of Suzhou dosed the first patient in an Australian clinical trial that combines its PD-L1 inhibitor with Bayer's Stivarga® in solid tumors; Coronavirus Outbreak • The Wuhan coronavirus (2019-nCoV) continued to spread, causing Wuhan to build two new pre-fab 1300-bed hospitals while biopharmas started research for new vaccines and repurposed immune therapies for immediate aid; • Ascletis of Hangzhou filed with China's NMPA to include its combination of two HIV protease inhibitors in the emergency channel as a treatment for the coronavirus; • BravoVax, a Wuhan vaccine developer, signed a letter of intent with Atlanta's GeoVax Labs to jointly develop a coronavirus vaccine. Stock Symbol: (NSDQ: SRNE) (SIX: ROG) (NSDQ: DMPI) (HK: 1093) (NSDQ: VSTM) (HK: 2616) (HK:1672) (OTC: GOVXD) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.